Pathfinder Cell Therapy Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010
Period Ending	Sep '15 Sep 30, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010
Revenue	-	-	0.05	0.11	0.07	-
Revenue Growth (YoY)	-	-	-52.63%	56.16%	-	-
Cost of Revenue	-	-	0.04	0.05	0.03	-
Gross Profit	-	-	0.02	0.06	0.05	-
Selling, General & Admin	0.61	0.86	1.03	1.04	1.58	0.13
Research & Development	0.16	0.26	0.59	1.08	1.4	0.69
Operating Expenses	0.78	1.12	1.62	2.12	2.98	0.83
Operating Income	-0.78	-1.12	-1.6	-2.06	-2.93	-0.83
Interest Expense	-0.31	-0.28	-0.2	-0.1	-0.11	-0.01
EBT Excluding Unusual Items	-1.08	-1.39	-1.79	-2.16	-3.04	-0.84
Merger & Restructuring Charges	-	-	-	-	-0.69	-
Impairment of Goodwill	-	-	-	-	-8.13	-
Asset Writedown	-	-	-0.16	-	-	-
Other Unusual Items	-	-	0.25	-	0.58	-0.46
Pretax Income	-1.08	-1.39	-1.71	-2.16	-11.27	-1.29
Net Income	-1.08	-1.39	-1.71	-2.16	-11.27	-1.29
Net Income to Common	-1.08	-1.39	-1.71	-2.16	-11.27	-1.29
Shares Outstanding (Basic)	667	667	667	667	526	458
Shares Outstanding (Diluted)	667	667	667	667	526	458
Shares Change (YoY)	-	-	-	26.81%	14.87%	4479.99%
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.02	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.02	-0.00
Gross Margin	-	-	31.48%	56.14%	64.38%	-
Operating Margin	-	-	-2961.11%	-1807.02%	-4015.07%	-
Profit Margin	-	-	-3157.41%	-1891.23%	-15438.36%	-
EBITDA	-0.77	-1.12	-1.59	-2.04	-2.91	-0.82
D&A For EBITDA	0	0	0.01	0.02	0.02	0.01
EBIT	-0.78	-1.12	-1.6	-2.06	-2.93	-0.83
Revenue as Reported	-	-	0.05	0.11	0.07	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.